Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Deferred Revenue: 2018-2023

Historic Current Deferred Revenue for Rocket Pharmaceuticals (RCKT) over the last 5 years, with Jun 2023 value amounting to $597,000.

  • Rocket Pharmaceuticals' Current Deferred Revenue changed negligibly% to $597,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $597,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $597,000 for FY2022, which is negligibly% changed negligibly from last year.
  • Rocket Pharmaceuticals' Current Deferred Revenue amounted to $597,000 in Q2 2023, which was down 0.00% from $597,000 recorded in Q1 2023.
  • In the past 5 years, Rocket Pharmaceuticals' Current Deferred Revenue ranged from a high of $597,000 in Q1 2021 and a low of $541,000 during Q1 2019.
  • For the 3-year period, Rocket Pharmaceuticals' Current Deferred Revenue averaged around $597,000, with its median value being $597,000 (2023).
  • Data for Rocket Pharmaceuticals' Current Deferred Revenue shows a peak YoY rose of 5.46% (in 2019) over the last 5 years.
  • Over the past 5 years, Rocket Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $562,000 in 2019, then grew by 4.98% to $590,000 in 2020, then grew by 1.19% to $597,000 in 2021, then remained steady at $597,000 in 2022, then remained steady at $597,000 in 2023.
  • Its Current Deferred Revenue stands at $597,000 for Q2 2023, versus $597,000 for Q1 2023 and $597,000 for Q4 2022.